Literature DB >> 6808052

Muscarinic receptor blockade by pirenzepine: effect on prolactin secretion in man.

A Masala, S Alagna, L Devilla, P P Rovasio, S Rassa, R Faedda, A Satta.   

Abstract

The effect of pirenzepine, a muscarinic receptor blocker which does not cross the blood brain barrier, on basal and TRH-stimulated prolactin (PRL) secretion in normal subjects was studied. Administration of 75 mg oral pirenzepine had no effects on prolactin levels in male subjects whereas it significantly reduced prolactin in females. No effect on TRH induced prolactin secretion was observed.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6808052     DOI： 10.1007/BF03350483

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  12 in total

1.  Blockade of the release of gonadotropins and prolactin by subcutaneous or intraventricular injection of atropine in male and female rats.

Authors:  C Libertun; S M McCann
Journal:  Endocrinology       Date:  1973-06       Impact factor: 4.736

2.  Inhibition of prolactin secretion by cholinergic drug.

Authors:  L Grandison; M Gelato; J Meites
Journal:  Proc Soc Exp Biol Med       Date:  1974-04

3.  [A study of the pharmacological activation of the central pole of the hypothalamo-hypophyseal axis].

Authors:  A Soulairac; C Schaub; P Franchimont; N Aymard; H van Cauwenberge
Journal:  Ann Endocrinol (Paris)       Date:  1968 Jan-Feb       Impact factor: 2.478

4.  Cholinergic control of the nocturnal prolactin surge in the pseudopregnant rat.

Authors:  B K McLean; M B Nikitovitch-Winer
Journal:  Endocrinology       Date:  1975-10       Impact factor: 4.736

5.  Methoscopolamine inhibition of sleep-related growth hormone secretion. Evidence for a cholinergic secretory mechanism.

Authors:  W B Mendelson; N Sitaram; R J Wyatt; J C Gillin; L S Jacobs
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

6.  Endogenous cholinergic modulation of growth-hormone secretion in normal and acromegalic humans.

Authors:  S A Leveston; P E Cryer
Journal:  Metabolism       Date:  1980-08       Impact factor: 8.694

7.  [Anti-ulcer agent pirenzepine (LS 519)--a tricyclic compound with particular physico-chemical properties (author's transl)].

Authors:  W Eberlein; G Schmidt; A Reuter; E Kutter
Journal:  Arzneimittelforschung       Date:  1977-02

8.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

9.  Muscarinic receptor binding in sheep anterior pituitary.

Authors:  D R Burt; R L Taylor
Journal:  Neuroendocrinology       Date:  1980-06       Impact factor: 4.914

10.  Effect of cyproheptadine and atropine on the diurnal prolactin responses to insulin-induced hypoglycemia in normal men.

Authors:  R S Nathan; M A Tabrizi; F S Halpern; E J Sachar
Journal:  J Clin Endocrinol Metab       Date:  1980-07       Impact factor: 5.958
View more
  3 in total

Review 1.  Drugs in Lactation.

Authors:  Philip O Anderson
Journal:  Pharm Res       Date:  2018-02-06       Impact factor: 4.200

Review 2.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 3.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.